• Home

  • Our Story

  • Dengue Fever

  • Solution

  • POCT

  • Investors

  • Partners

  • News

  • Contact

  • More

    Logo _trans.png
    Delivering Innovative Diagnostics for Personalized Curative Therapies
    Dengue Fever - A global fast-emerging pandemic-prone viral disease
    20,000
    world-36479_1280.png
    400,000,000

    people have Dengue infections every year

    500,000

    people progressed on to develop Severe Dengue and required hospitalization

    hospitalized Severe Dengue patients die from the disease

    US$14,600,000,000

    worth of socioeconomic cost

    Source: Malaria Consortium

    The Challenge

    malaria.png

    Currently, doctors are unable to predict the progress of the disease due to the lack of a Severe Dengue prediction test. Patients often end up being admitted to hospital even when they do not progress to Severe Dengue. This leads to overhospitalization in both developing and developed countries.

    Read More

    The Solution

    syringe.png

    StratifiCare™ has discovered a panel of biomarkers which are able to determine the progress of Dengue Fever. Patients who are predicted not to progress to Severe Dengue can be managed at outpatient settings instead. This reduces the overhospitalization issue faced by hospitals and relieves healthcare burden in countries.

    Read More

    SUPPORTING THE SDGS

    The United Nations has defined a set of 17 Sustainable Development Goals (SDGs) that address global social and economic development issues. As a responsible medical technology provider, StratifiCare adopts the SDG framework.


    By developing quality, innovative diagnostic solutions, we pledge to facilitate access to quality essential health services, for the general and the most disadvantaged population. 

    NEWS
    Logo _trans.png
    • Instagram - Grey Circle
    • Twitter - Grey Circle
    • Facebook - Grey Circle
    • LinkedIn - Grey Circle

    © 2015-2019 StratifiCare™ Inc.

     Home   Our Story   Dengue Fever   Solution   POCT   Investors   Partners   News   Contact